Transcatheter Microguidewire Drilling for Transseptal Left Atrial Access

Not Applicable

• Conditions: Atrial Septal Dilatation; Heart Diseases

• Registration Number: NCT04561908
• Lead Sponsor: China National Center for Cardiovascular Diseases

Brief Summary

This study aims to investigate the safety and efficacy of transcatheter microguidewire drilling (TMD) for transseptal left atrial access in patients with abnormal atrial septal morphology.

Detailed Description

Despite the widespread application and decades of experience, Brockenbrough-needle transseptal puncture still risks cardiac perforations and secondary pericardial effusion/tamponade, especially in patients with abnormal atrial septal morphology. To facilitate atrial septal crossing, different methods and devices have been developed, including radiofrequency energy, excimer laser, SafeSept wire and so on. However, these are still limited by availability and cost, and the advantages might be further offset by the potential risks. In addition, these methods are performed mainly with the linear insertion technique, which might result in less forward-force to penetrate atrial septum and displacement of needle-tip. Therefore, it is necessary to develop a safe, available and low-cost transseptal procedure for these patients.

Through a Brockenbrough needle, the hard "back-end" of the microguidewire (0.014-inch) has the potential to drill through the atrial septum with ease. Compared with a standard linear insertion technique, the penetration might be improved and less force is required with the bidirectional rotation technique, and the related risks might be reduced with the modified TSP due to the thin microguidewire. After the passage of the needle, the soft-end of microguidewire can be introduced into left pulmonary superior vein, which can become a safe rail for the introduction of puncture dilator/sheath.

In this study, we examined the effectiveness and safety of microguidewire-assisted TSP for patients with complex atrial septum.

Study Timeline

• Study Start: 2020-09-04
• Study First Submitted: 2020-09-20
• Study First Submitted QC: 2020-09-22
• Study First Posted: 2020-09-24
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-23
• Last Update Posted: 2022-04-29
• Primary Completion: 2022-09-04
• Study Completion: 2022-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Patients with atrial septal aneurysm (a bulging of the atrial septum of at least 10 mm beyond the plane of the atrial septum into either the right or left atrium); 2) Or patients with previous multiple transseptal punctures (≧2); 3) Or patients with thickened atrial septum (thickness ≧3 mm); 4) Or patients with enlarged right atrium (≧ 6 cm) and diminished left atrium (< 3 cm); 5) Or patients with prior mitral valve surgery; 6) Or patients with atrial baffles.

Exclusion Criteria

1. Associated atrial septal defect or patent foramen ovale; 2) Associated interrupted inferior vena cava; 3) Presence of implanted cardiac devices; 4) Echocardiographic evidence of intracardiac thrombus, mass, tumor or vegetation; 5) Thromboembolic events within the last 6 months; 6) Patients unable to grant informed, written consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Procedural Success	1 Day of procedure	Number of participants with successful transseptal left atrial access
Related-complications	1 Day of procedure	Pericardial effusion

Secondary Outcome Measures

Name	Time	Method
Transseptal Access Procedure Time	1 Day of procedure	Total amount of procedure time, from the beginning of the transseptal procedure until left atrium access is obtained in each patient.

Trial Locations

Locations (2)

National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences,Fuwai Hospital; 🇨🇳 Beijing, Beijing, China

Yan Chaowu; 🇨🇳 Beijing, Select A State Or Province, China